Covid-19 Vaccination Options for Immunosuppressed Cancer Patients

I Dewa Agung Panji Dwipayana, I Dewa Ayu Agung Diah Sutarini

Abstract views = 1087 times | downloads = 667 times


Background: Currently, many COVID-19 vaccine candidates are being developed to end the pandemic; however, immunosuppressed cancer patients have been excluded from the participating criteria. It is important that they are able to examine their options for achieving immunity against COVID-19. Purpose: This review aims to discuss the available options that can be taken to vaccinate immunosuppressed cancer patients when no vaccine is being developed for their safety. Method: A literature study was conducted using Google Scholar, DOAJ, and GARUDA Library on November 2, 2020, focusing on articles examining vaccination guidelines for immunosuppressed cancer patients. Results: The search found 200 articles, which were curated to obtain 13 articles that satisfied all inclusion criteria. These consist of four guidelines, five reviews, and four research articles. Based on the literature, immunosuppressed cancer patients have the option to use the vaccines currently under development, with precautions set for live attenuated and potentially infectious vaccines. Vaccination timing also needs to be adjusted so as to fall at a certain time before or after the immunosuppressive condition. Moreover, a more complete COVID-19 immunity can be achieved through a synergy between individual vaccination and the construction of herd immunity. Conclusion: Most of the vaccines currently under development may be safe for cancer patients, being mindful of several considerations. Here, herd immunity can serve as a complement to individual immunity.


covid-19; vaccine; immunization; immunosuppressed; cancer

Full Text:



Alexander, K. E., Tong, P. L., Macartney, K., Beresford, R., Sheppeard, V., & Gupta, M. (2018). Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine, 36(27), 3890–3893.

Ariza-Heredia, E. J., & Chemaly, R. F. (2015). Practical review of immunizations in adult patients with cancer. Human Vaccines and Immunotherapeutics, 11(11), 2606–2614.

Baden, L. R., Swaminathan, S., Angarone, M., Blouin, G., Camins, B. C., Casper, C., … Smith, C. (2016). Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 14(7), 882–913.

Bitterman, R., Eliakim-Raz, N., Vinograd, I., Zalmanovici Trestioreanu, A., Leibovici, L., & Paul, M. (2018). Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews, 2018(2), 1–47.

Carr, S., Allison, K. J., Van De Velde, L. A., Zhang, K., English, E. Y., Iverson, A., … Flynn, P. M. (2011). Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Journal of Infectious Diseases, 204(10), 1475–1482.

CDC COVID-19 Response Team. (2020). Prevalence of selected underlying health conditions among patients with Corona virus disease 2019 - United States, February 12-March 28, 2020. Morbidity and Mortality Weekly Report, 69(13), 382–386.

Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., … Cai, H. (2020). Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery, 10(6), 783–791.

Dwipayana, I. D. A. P. (2020). Efforts in securing vaccine for covid-19 outbreak in Indonesia. Health Notions, 4(10), 313–317.

Esposito, S., Bonanni, P., Maggi, S., Tan, L., Ansaldi, F., Lopalco, P. L., … Gavazzi, G. (2016). Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid vaccine study group (EVASG), European geriatric medicine society (EUGMS) and the World association for infectious diseases and immunological disorders (WAidid). Human Vaccines and Immunotherapeutics, 12(7), 1777–1794.

Failing, J. J., Ho, T. P., Yadav, S., Majithia, N., Riaz, I. Bin, Shin, J. Y., … Xie, H. (2020). Safety of influenza vaccine in patients with cancer receiving pembrolizumab. JCO Oncology Practice, 16(7), e573–e580.

Hale, L. P., Rajam, G., Carlone, G. M., Jiang, C., Owzar, K., Dugan, G., … Sempowski, G. D. (2019). Late effects of total body irradiation on hematopoietic recovery and immune function in rhesus macaques. PLoS ONE, 14(2), 1–17.

Kotecha, R. S., Wadia, U. D., Jacoby, P., Ryan, A. L., Blyth, C. C., Keil, A. D., … Richmond, P. C. (2016). Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Medicine, 5(2), 285–293.

Lee, L. Y. W., Cazier, J. B., Starkey, T., Briggs, S. E. W., Arnold, R., Bisht, V., … Hudson, Z. (2020). COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumor subtype and patient demographics: a prospective cohort study. The Lancet Oncology, 21(10), 1309–1316.

Leung, T.-F., Li, C.-K., Hung, E. C. W., Chan, P. K. S., Mo, C.-W., Wong, R. P. O., & Chik, K.-W. (2004). Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. European Journal of Haematology, 72(5), 353–357.

Lopez, A., Mariette, X., Bachelez, H., Belot, A., Bonnotte, B., Hachulla, E., … Peyrin-Biroulet, L. (2017). Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. Journal of Autoimmunity, 80, 10–27.

Marco-Franco, J. E., Guadalajara-Olmeda, N., Julián, S. G. de, & Vivas-Consuelo, D. (2020). COVID-19 healthcare planning: Predicting mortality and the role of the herd immunity barrier in the general population. Sustainability (Switzerland), 12(13), 1–10.

Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuna-Villaorduna, A., … Verma, A. (2020). Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discovery, 10(7), 935–941.

Mikulska, M., Cesaro, S., de Lavallade, H., Di Blasi, R., Einarsdottir, S., Gallo, G., … Cordonnier, C. (2019). Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases, 19(6), e188–e199.

Mussai, F., De Santo, C., Abu-Dayyeh, I., Booth, S., Quek, L., McEwen-Smith, R. M., … Cerundolo, V. (2013). Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood, 122(5), 749–758.

Papp, K. A., Haraoui, B., Kumar, D., Marshall, J. K., Bissonnette, R., Bitton, A., … Wade, J. (2019). Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. Journal of Cutaneous Medicine and Surgery, 23(1), 50–74.

Pergam, S. A., Englund, J. A., Kamboj, M., Gans, H. A., Young, J. A. H., Hill, J. A., … Carpenter, P. A. (2019). Preventing measles in immunosuppressed cancer and hematopoietic cell transplantation patients: a position statement by the American society for transplantation and cellular therapy. Biology of Blood and Marrow Transplantation, 25(11), e321–e330.

Robin, C., Beckerich, F., & Cordonnier, C. (2015). Immunization in cancer patients: Where we stand. Pharmacological Research, 92, 23–30.

Sandherr, M., Hentrich, M., von Lilienfeld-Toal, M., Massenkeil, G., Neumann, S., Penack, O., … Cornely, O. A. (2015). Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the guidelines of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO). Annals of Hematology, 94(9), 1441–1450.

van Riel, D., & de Wit, E. (2020). Next-generation vaccine platforms for COVID-19. Nature Materials, 19(8), 810–812.

Vollaard, A., Schreuder, I., Slok-Raijmakers, L., Opstelten, W., Rimmelzwaan, G., & Gelderblom, H. (2017). Influenza vaccination in adult patients with solid tumours treated with chemotherapy. European Journal of Cancer, 76, 134–143.

Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H., & Smit, E. F. (2018). Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events. European Journal of Cancer, 104, 182–187.

World Health Organization. (2020a). Weekly operational update on Coronavirus disease (COVID-19) - November 20, 2020. World Health Organization. Geneva. Retrieved September, 12, 2020, from

World Health Organization. (2020b). WHO draft landscape of COVID-19 candidate vaccines – 12 November 2020. World Health Organization. Geneva. Retrieved September, 12, 2020 from

You, B., Ravaud, A., Canivet, A., Ganem, G., Giraud, P., Guimbaud, R., … Lotz, J. P. (2020). The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. The Lancet Oncology, 21(5), 619–621.

Zhang, M., Fan, Y., Che, X., Hou, K., Zhang, C., Li, C., … Qu, X. (2020). 5-FU-induced upregulation of exosomal PD-L1 causes immunosuppression in advanced gastric cancer patients. Frontiers in Oncology, 10, 1–15.


  • There are currently no refbacks.



                                                                    Creative Commons License
JBE by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International

                                          Fakultas Kesehatan Masyarakat Universitas Airlangga

                                                         Kampus C Universitas Airlangga

                                        Jl. Mulyorejo Kampus C Unair, Surabaya 60115, Indonesia.

                                            E-mail: /

                                                            Phone: +62 877-3928-1082


Visit JBE Stats